G71.0349
Limb girdle muscular dystrophy due to other sarcoglycan dysfunction
Clinical Classification Guidelines
Inclusion Terms
- Delta sarcoglycanopathy
- Delta-sarcoglycan-related LGMD R6
- Gamma sarcoglycanopathy
- Gamma-sarcoglycan-related LGMD R5
- Limb girdle muscular dystrophy type 2C
- Limb girdle muscular dystrophy type 2F
Medical Intelligence & Overview
Limb girdle muscular dystrophy (LGMD) is a group of inherited disorders characterized by progressive weakness and wasting of the muscles around the hips and shoulders. Specifically, the type associated with sarcoglycan dysfunction, such as ICD-10 code G71.0349, is caused by mutations affecting specific proteins within muscle cells called sarcoglycans. These proteins are part of the dystrophin-associated glycoprotein complex, which helps maintain muscle integrity during contraction. When these proteins are abnormal or deficient, it leads to muscle weakness and degeneration over time. Variants under this classification include delta and gamma sarcoglycanopathies, which are also known as LGMD R6 and LGMD R5, respectively.
Causes & Symptoms
Clinical Causes: Inherited genetic mutations affecting sarcoglycan genes (such as SGCA, SGCB, SGCD, or SGCG). Autosomal recessive inheritance pattern, meaning a person must inherit two copies of the mutated gene to develop the disorder. Mutations lead to dysfunctional or absent sarcoglycan proteins, compromising muscle cell membrane stability.
Key Symptoms: Progressive muscle weakness, primarily in the shoulders, hips, thighs, and calves. Difficulty rising from sitting or lying positions. Muscle wasting or atrophy in affected areas. Potential development of difficulties with mobility and balance. In some cases, joint contractures or scoliosis may occur. Fatigue during physical activity.
Diagnostic & Treatment
Diagnosis Path: Clinical evaluation to assess muscle strength and progression. Muscle biopsy to observe muscle tissue and protein presence. Blood tests for elevated muscle enzymes like creatine kinase (CK). Genetic testing to identify mutations in sarcoglycan genes. Electromyography (EMG) to evaluate electrical activity of muscles.
Treatment Protocols: Currently, there is no cure; management focuses on symptom relief and maintaining quality of life. Physical therapy to improve muscle strength and prevent contractures. Assistive devices, such as braces or wheelchairs, to support mobility. Monitoring and treating complications like scoliosis or cardiomyopathy if they develop. Participation in clinical trials may be an option for emerging therapies.
Clinical Advice & FAQs
Billing Guidance
Is G71.0349 a billable ICD-10 code?
Yes, G71.0349 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G71.0349?
Clinical documentation must specify the nature of Limb girdle muscular dystrophy due to other sarcoglycan dysfunction and any associated comorbidities for accurate reporting.
Cite this Clinical Reference